SCHEMBL4133619

SCHEMBL4133619

COc1ccc(OC)c(C(=O)C2CC2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.66
LMNA P02545 2/20 0.66
KDM4E B2RXH2 2/20 0.66
HTT P42858 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CPS1 P31327 1/20 0.53
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.53
ABCG2 Q9UNQ0 1/20 0.51
POLB P06746 1/20 0.51
KDM2B Q8NHM5 3/20 0.50
ALOX15 P16050 1/20 0.49
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113759 0.92 MAPT (0.61) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL5995248 0.87 MAPT (0.63) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL4129937 0.86 MAPT (0.55) MAPTLMNAKDM4EHTTNPSR1
SCHEMBL17682929 0.85 CPS1 (0.59) MAPTLMNAKDM4EHTTALDH1A1
SCHEMBL4126643 0.83 NPC1 (0.53) MAPTLMNAKDM4EHTTALDH1A1
SCHEMBL4841620 0.82 CPS1 (0.52) MAPTLMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL30513999 0.82 CPS1 (0.75) CPS1RAB9ANPC1
SCHEMBL20855978 0.82 ALDH1A1 (0.60) MAPTLMNAKDM4EALDH1A1MEN1
SCHEMBL12859803 0.80 ALDH1A1 (0.58) LMNAKDM4EHTTALDH1A1CPS1
SCHEMBL6987660 0.78 KDM2B (0.58) MAPTLMNAKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221596-A1 Substtituted aryl oximes BAYER CROPSCIENCE AG (DE) 2009-09-03 US disclosed
US-20090221596-A1 Substtituted aryl oximes BAYER CROPSCIENCE AG (DE) 2009-09-03 US disclosed
US-20090221596-A1 Substtituted aryl oximes BAYER CROPSCIENCE AG (DE) 2009-09-03 US disclosed
CN-101193855-A Substituted aryl oximes BAYER CROPSCIENCE AG (DE) 2008-06-04 CN disclosed
EP-1883622-A1 SUBSTITUTED ARYL OXIMES Bayer CropScience Aktiengesellschaft (DE) 2008-02-06 EP disclosed
WO-2007090434-A1 SUBSTITUTED ARYL OXIMES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221596-A1 Substtituted aryl oximes CYP1A1, PRDX1, CYP1A2 MAPT 3870/4885LMNA 2761/4885KDM4E 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.